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Abstract
Nonalcoholic fatty liver disease (NAFLD) is characterized by fat deposition in hepatocytes, and a strong association
with nutritional factors. Dietary fatty acids are classified according to their biochemical properties, which confer
their bioactive roles. Monounsaturated fatty acids have a dual role in various human and murine models. In
contrast, polyunsaturated fatty acids exhibit antiobesity, anti steatosic and anti-inflammatory effects. The
combination of these forms of fatty acids—according to dietary type, daily intake and the proportion of n-6 to n-3
fats—can compromise hepatic lipid metabolism. A chemosensory rather than a nutritional role makes bioactive
fatty acids possible biomarkers for NAFLD. Bioactive fatty acids provide health benefits through modification of fatty
acid composition and modulating the activity of liver cells during liver fibrosis. More and better evidence is
necessary to elucidate the role of bioactive fatty acids in nutritional and clinical treatment strategies for patients
with NAFLD.
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Introduction
Nonalcoholic fatty liver disease (NAFLD) is a condition
characterized by deposition of fat in hepatocytes of pa-
tients with no history of excessive alcohol consumption.
NAFLD causes progressive liver tissue damage from
simple steatosis to nonalcoholic steatohepatitis (NASH),
which involves several inflammatory processes, and
might progress rapidly to develop advanced liver fibrosis,
cirrhosis and hepatocellular carcinoma [1]. NAFLD is as-
sociated with obesity, type 2 diabetes, hypertension and
dyslipidemia; is considered the hepatic manifestation of
metabolic syndrome, and it has a strong association with
nutritional factors [2].
Fats have been considered to be sources of energy and
components of biological membranes, however research
over recent years demonstrate a diverse array of bio-
logical activities associated with fatty acids, their deriva-
tives and other types of lipid compounds. Bioactive fatty
acids encompasses a range of structures, from simple
saturated fatty acids to complex molecules derived from
various biological compounds, playing important roles in
energy homeostasis, cell proliferation, metabolic homeo-
stasis and in the regulation of inflammatory processes
[3, 4]. Therefore bioactive fatty acids modify lipid com-
position, providing a biological effect in cell signaling
pathways.
Dietary fatty acids are involved in hepatic lipogenesis
and might play a dual role in the pathogenesis of liver
steatosis as they are involved in their development and
in preventing or reversing hepatic fat accumulation. Diet
fatty acid composition is an important component in
NAFLD development, since 15 % of liver triacylglycerol
comes from the diet [5]. Patients with NASH, claim a
diet richer in fat and poorer in complex carbohydrates
and protein that the general population [6].
The liver is exposed to various types of lipids (fatty
acids, cholesterol and triacylglycerol’s) from the diet and
visceral adipose tissues, via the hepatic portal vein, an
excessive free fatty acid flux into the liver via the hepatic
portal vein can cause fatty liver disease and hepatic insu-
lin resistance [7].
The dietary fatty acids differ biochemically and they
are classified by the number of carbon atoms (defining
their length), the configuration of hydrogen atoms
around the carbon–carbon, double or triple bonds and
the positions of unsaturated bonds relative to the methyl
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end of the hydrocarbon chain [8, 9]. These biochemical
differences, condition their biological activities.
The aim of this review was to determine the role of
bioactive dietary fatty acids on the modulation of bio-




Undigested food or dietary carbohydrates in the small
intestine undergo subsequent fermentation in the colon
by its microbiota and give rise to various microbial me-
tabolites such as short-chain fatty acids (SCFAs), includ-
ing acetic, propionic and butyric acid [10]. These are
absorbed rapidly, mostly by nonionic diffusion, but also
by active transport mediated by a sodium-coupled trans-
porter [11]. Changes in gut’s microbiota can lead to ex-
cessive energy production with negative effects on
metabolism and obesity, promoting liver steatosis [12].
In murine models, feeding a mixture of SCFAs de-
creased the hepatic cholesterol synthesis rate [13], while
high fat consumption promotes harmful inflammatory
effects that seem to be partly counteracted by SFCAs,
specifically propionic and butyric acids [14]. Thus,
NAFLD has been associated with a shift in the gut
microbiota profile, and treatment with probiotics has
been suggested to prevent the progression of this liver
disease [15, 16].
Butyrate/butyric acid
Among SCFAs, butyrate is the primary energy source of
colonocytes, it is one of the main products of fiber fer-
mentation, as well is a poorly digestible polysaccharide
in the colon and distal small intestine [17], specifically of
digestion-resistant starches and dietary fiber types, but
also it comes to some extent from dietary and endogen-
ous proteins. After the absorption of butyrate by the
colon, colonocytes metabolize it in part and the
remaining fraction reaches the liver via the hepatic por-
tal vein [7]. In particular, butyrate has the ability to en-
hance the growth of lactobacilli and bifidobacteria in the
colon [11], also has various beneficial metabolic effects
such as improving thermogenesis and energy expend-
iture, which contributes to reduce body weight and other
markers of metabolic syndrome [18]. For instance, the
probiotic strain Clostridium butyricum (MIYAIRI 588)
produce butyrate in a murine model of a choline-
deficient/L-amino acid defined diet, which prevents the
progression of liver damage through a reduction in hep-
atic lipid deposition and improve triacylglycerol content
and insulin resistance [15]. Sodium butyrate and a syn-
thetic butyrate derivative showed beneficial effects on
subjects with NAFLD, preventing liver inflammation,
metabolic impairment and reducing insulin resistance
[15]. Moreover, butyrate induced the production of
fibroblast growth factor 21, which is involved in stimu-
lating hepatic fatty acid β-oxidation [19].
Propionate/propionic acid
Propionic acid (PA) is produced naturally in a few food
products, such as milk in small amounts, but in higher
levels on dairy products like yogurt and cheese following
bacterial fermentation, mainly by propionibacteria [20].
Undigested carbohydrates, such as dietary fiber and
digestion-resistant starch represent the major sources of
PA [20]. The quantity of PA produced depends on the
microbiota, the type and quantity of the substrates and
gut transit time [21]. The liver metabolizes around 90 %
of PA and the rest is transported into the peripheral
blood system [10].
Propionate is involved in hepatic cholesterol synthesis
rate [13] and in high-density lipoprotein and triacylglyc-
erol levels regulation [22]. It has been considered a sub-
strate for hepatic gluconeogenesis, but it seems to have
two competing and contrasting effects, regards of being
a substrate or inhibitor of gluconeogenesis [21]. More-
over, a role in other disorders such as poor control of sa-
tiety has been studied [23]. Clearly, a well-designed
study to test the efficacy of SCFAs in treating liver dis-
eases is imperative.
Acetate/acetic acid
Acetic acid is frequently ingested in the diet given that
vinegar is a common condiment; however oral com-
mensal bacteria are another source of acetate [24]. Acet-
ate is considered the most abundant SCFA in the
foregut lumen and the principal in the colon. It is
absorbed immediately after ingestion and is transported
directly to the liver, so is less metabolized in the colon
[21]. Even though it is believed to be similar to propion-
ate on having a low-level role in cholesterol metabolism,
it seems that acetate is more effective in this regard. [25]
Moreover, acetate in the intestinal lumen activates mul-
tiple mucosal responses, including the release of gut hor-
mones and afferent nerve activation [26].
Medium-chain fatty acids
Medium-chain fatty acids (MCFAs), with 8–10 carbon
atoms, are found as triacylglycerols in many foods. They
are found in palm kernels and coconut oil, butter, fresh
cream and milk, which are considered the main sources
of MCFA [9]. Medium-chain triacylglycerols (MCTs)
have rapid absorption and high solubility, which pre-
cludes their rapid hydroxylation to MCFAs. They are
transported directly into the liver via the hepatic portal
vein, here they are metabolized rapidly by β-oxidation,
increasing diet-induced thermogenesis [27]. There is evi-
dence that MCFAs are essentially oxidized to acetyl-
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coenzyme A within hepatic mitochondria and further
degraded to CO2 or converted to ketone bodies [28].
Dietary MCTs induce thermogenesis and do not contrib-
ute to weight gain because they are not deposited in adi-
pose tissues; therefore, MCTs might be used as a
medium of preventing and treating obesity [18].
After consumption of a MCT-rich oil diet in mice,
plasma triacylglycerol levels were elevated, as were hepatic
lipogenic enzymes activities, acetyl-coenzyme A carboxyl-
ase, fatty acid synthase and diacylglycerol acyltransferase;
however the levels of plasma and hepatic cholesterol were
reduced [28]. A MCFA-rich diet with replacement of diet-
ary long-chain triacylglycerols has been shown to reduce
the levels of steatosis and the markers of hepatic injury,
such as hepatic transaminases. This replacement appeared
to result in a substantial upregulation of fatty acid liver oxi-
dation, sufficient to reduce the development of steatosis
[29]. The substitution of saturated for unsaturated fats pro-
vides a dose-responsive protective effect on the develop-
ment of alcoholic liver disease in a murine model of
ethanol consumption in vivo [30]. The severity of steatosis
varies widely depending on the dietary saturated fat con-
tent, so delineation of the type of dietary fat is an important
factor that affects hepatic pathology by inducing or promot-
ing the development and progression of NAFLD (Fig. 1).
In a study performed in slightly obese subjects with a body
mass index ≥25 kg/m2, the body weight loss was higher in
the group that was eating bread (containing 14 g of oil as
MCTs daily) for breakfast, than in the group ingesting long-
chain triacylglycerols (LCTs) [31]. As MCTs increase energy
expenditure, this could result in a faster feeling of satiety and
facilitate weight control, when included in the diet as a sub-
stitute for fats containing LCTs [32]. MCTs have certain dis-
advantages when cooked, that it has limited their general
use [9], such as a low smoking point and excessive foaming
when used for deep frying, a balance between MCTs and
LCTs could help in suppressing body fat accumulation.
MCFAs have been employed in certain clinical tests. For
example, C-octanoic acid has been used as a substrate in non-
invasive breath testing to assess total body β-oxidation in
subjects with NASH [33]. In animal models, the therapeutic
supplementation of caprylic acid could effectively decrease the
levels ofCampylobacter species of pathogenic bacteria [34].
Long-chain fatty acids
Long-chain fatty acids (LCFAs) are molecules containing 12
or more linearly arranged carbon atoms, which are found
mostly as components of the triacylglycerols of edible oils
and fats [18]. Long-chain triacylglycerols are hydrolyzed at
the 1,3-ester bond of glycerol by pancreatic lipase in the
small intestine, mainly to 2-monoacylglycerol. This product
together with other fatty acids are dissolved in micelles and
absorbed by mucosal cells in the small intestine. LCFAs are
re-synthesized to triacylglycerol, form chylomicrons and
then are released into the circulation via the lacteal lymph
vessels and transported to peripheral tissues [9].
Fatty acid composition is characterized by the degree
of unsaturation in the fatty acid chain and the molecular
configuration at the bonds [8], where fatty acids may be
saturated (no double bonds) or unsaturated (one or
more double bonds). These features produce specific
biological functions.
Fig. 1 Bioactive fatty acid patterns according to nonalcoholic fatty liver disease (NAFLD) inhibtion and promotion. Key: The color bars tapering
toward either side of the outcome line indicate a decline in activity of the NAFLD stage (orange) according to each fatty acid. The bioactive fatty
acids panel includes SCFAs, MCFAs, and LCFAs. Key: NAFLD, nonalcoholic liver disease; SCFA, short-chain fatty acid; MCFA, medium-chain fatty
acid; LCFA, long-chain fatty acid
Juárez-Hernández et al. Nutrition Journal  (2016) 15:72 Page 3 of 10
Monounsaturated fatty acids
Oleic acid is a monounsaturated fatty acid that naturally
occur in various animal and vegetable fats and oils. Pre-
vious studies have shown a dual role of oleic acid. Thus,
in murine and human hepatocyte models, treatment
with palmitic acid triggered the early activation of stress-
related kinases and apoptosis, which were attenuated by
oleic acid treatment [35]. Oleic acid was able to induce
liver X-receptor alpha mRNA synthesis in human neu-
trophils, but it led to decreased intracellular lipid levels
and inflammation markers [36]. Conversely, in an in
vitro model, oleic acid induced hepatic steatosis through
aquaporin 3 and 9 via p38-signaling regulation [37]. In
an in vitro model of steatosis, induced by oleic acid,
treatment with phenolic acids led to increased fatty acid
oxidation and the synthesis of triacylglycerol and choles-
terol [38]. Moreover, high plasma levels of oleic acid
were observed in a clinical study including 10 patients
with NAFLD and 9 with NASH [39]. Further studies are
needed to understand the cellular and physiological pro-
cesses involving oleic acid and elucidate its role in
NAFLD.
Polyunsaturated fatty acids
Polyunsaturated fatty acids (PUFAs) include linoleic acid
(n-6), alpha-linolenic acid and arachidonic acid. The
simplest n-6 fatty acid is linoleic acid (C18:2), while lino-
lenic acid (C18:3) is the simplest n-3 fatty acid. Murine
models have demonstrated effects against obesity [40],
steatosis and infflamation from n-3 fatty acids [41]. In
addition, dietary supplementation with PUFAs combined
with hypocaloric diets had a beneficial effect on plasma
lipid profiles [42].
Several types of oils containing PUFAs have shown to
prevent the onset of NAFLD. Canola oil, which is pro-
duced from the seeds of several varieties of plants, con-
tains linoleic acid (n-6) and α-linolenic acid (n-3) in a
2:1 ratio. Hanke et al. observed that hepatic steatosis
was attenuated in mice treated with different variants of
canola oil; however, increased levels of eicosapentaenoic
acid (EPA) and docosahexaenoic acid (DHA) were not
correlated with markers of inflammation or with mRNA
levels encoding for desaturated or elongated PUFAs [43].
Krill oil, which also contains n-3 PUFAs, EPA and
DHA, has beneficial effects on glucose and lipid metab-
olism, as well on the mitochondrial respiratory chain
[44]. These effects could be explained by the stimulation
and catabolism of excess fats introduced by a hypercalo-
ric diet, while the fatty acid synthesis de novo is inhib-
ited [5]. Moreover, the combination of DHA and EPA
with alpha-linolenic acid can lower the risk of fatal is-
chemic episodes [45].
However, the role of PUFAs in diet is still controversial
and their effects on inflammation and fibrosis during
steatohepatitis remain unresolved. In a steatohepatitis
murine model fed with a methionine-choline-deficient
(MCD) diet supplemented with olive oil (OO) and/or n-
3 PUFAs, higher alanine transaminase levels where in-
duced and more severe scores of inflammation, includ-
ing a significant increase in lipogranulomas number and
intrahepatic gene expression of proinflammatory and
profibrogenic molecules, that when the diet was supple-
mented only with OO [46].
Recently it has been observed that some oxidized
lipids from PUFA’s, play an important role on inflamma-
tory pathways, therefore, these could be associated to
the development and progression of NAFLD, however
more studies are needed to establish the association with
oxidized lipids and the progression of NAFLD to NASH
or HCC [47].
The ‘daily recommended intake’ is a very important
concept to consider; a cross-sectional study evaluated
the dietary intake in patients with NAFLD, showing that
more than 80 % of them did not reach the daily recom-
mended intake of linolenic and linoleic acids [48]. How-
ever, the intake of PUFAs was higher in NAFLD
patients, suggesting that this factor alone might not be a
determinant for NAFLD. Thus, new bioactive molecules
need to be discovered in this context [48].
n-6 versus n-3 fatty acids
Because dietary n-3 PUFAs are able to limit triacylglycerol
storage in the liver, it is necessary to consider the n-3/n-6
ratio, given that high n-6 levels could induce NAFLD and
other chronic diseases [5]. A higher n-3/n-6 ratio in the
diet is desirable as a way of improving human health by
reducing the weight of intra-abdominal fat, reducing adi-
pocyte size and normalization of the heartbeat. This is be-
cause n-3 PUFAs are usually converted to anti-
inflammatory eicosanoids while n-6 PUFAs are converted
to proinflammatory eicosanoids [49].
The n-3/n-6 ratio has an important association with
the development of NAFLD, where a diet with a higher
n-6/n-3 ratio and suboptimal PUFA intake could result
in a hepatic lipid metabolism dysregulation, insulin
homeostasis and inflammatory pathways disarrangement
[48]. Patients with NAFLD showed a significant decrease
in the n-6/n-3 ratio, the same scenario was observed in
patients with NASH compared with healthy controls
[39]. Although patients with NASH had a lower intake
of either n-3 or n-6 fatty acids than controls, such pa-
tients had a significantly higher intake of n-6 fatty acids
and a decreased n-6/n-3 ratio versus controls have been
reported, which have been shown to have a negative im-
pact on health maintenance and disease prevention [6].
The increased n-6/n-3 ratios in patients with liver dis-
eases have different causes, such as inadequate intake of
precursors and a higher intake of n-9 trans isomers [39].
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It is clear that is necessary to maintain an adequate n-6/
n-3 ratio to avoid the development of insulin resistance
and the activation of inflammatory pathways involved with
fat deposition in the liver. Allard et al. suggested that n-3
dietary supplementation in addition to lifestyle modifica-
tions might be beneficial in preventing the progression of
steatosis and ensures an adequate balance between these
fatty acids [50]. Despite the findings about the effect of
PUFA’s on NAFLD prevention, it is not clear if an ad-
equate diet including PUFA’s could reverse the progres-
sion stages of NASH or liver fibrosis [47].
With respect to n-6 PUFAs, pinolenic acid is charac-
terized by having polymethylene-interrupted double
bonds, it is contained in pine seed oil, exhibiting benefi-
cial effects on lipid metabolism [51]. In a murine model
with a diet that contains pine seed oil, a significant in-
crease in the splenic production of immunoglobulins
and leukotrienes was shown [52]. Moreover, in a murine
model, pinolenic acid exerted antidiabetic effects as well
as some beneficial metabolic effects such as reducing
weight gain and intramuscular lipid accumulation [53].
These findings suggest that pine seed oil might have po-
tential effects as a dietary supplement to counteract
obesity and metabolic dysregulation [54].
Bioactive fatty acids as biomarkers
Based on studies suggesting that bioactive dietary fatty acids
can suppress the accumulation of abdominal adipose tissue
and serum lipids, the primary function of bioactive fatty
acids absorbed by the duodenum might be chemosensory
rather than nutritional [26]. Thus, the proposal of using
bioactive fatty acids as biomarkers in patients with NAFLD
could be attractive. Glucagon-like peptide 1 (GLP1) is in-
volved in the development of NASH, administration of a
peptide agonist of the GLP1 receptor (Exendin-4) improved
steatohepatitis through the increase of hepatic long chain
saturated fatty acid levels and a hepatic n-3/n-6 PUFA ratio
reduction, specifically by the regulation of hepatic fatty acid
metabolism [55]. Furthermore, high levels of acid sphingo-
myelinase are present in the serum of patients with NAFLD
[55, 56]. While treatment with a cholesteryl ester transfer
protein reduced HDL levels, it might also increase the risk
of atherosclerosis [57].
There are important roles for the phospholipase A family
(PLA) in several diseases. Phospholipase A2 (PLA2) levels
were significantly increased in patients after ischemic liver
tissue versus nonischemic controls [58]. Moreover, PLAs
have distinct roles in diet-induced obesity, such as counter-
acting adipose tissue inflammation, insulin resistance,
hyperlipidemia and obesity through facilitating lipid accu-
mulation in adipose tissue [59]. Another phospholipase
member, calcium-independent phospholipase A2 has been
shown to act as an upstream checkpoint for mechanisms
that regulate fatty acid uptake [60].
Mechanisms involving receptor recognition
The nutrient receptors include all known G protein-
coupled receptors (GPCRs) or free fatty acid receptors,
which are a large class of seven transmembrane proteins
that regulate a diverse range of signaling events and are
important in mediating autocrine, paracrine and endo-
crine functions [61]. These have specificity according to
free fatty acid or lipid molecule type binding and activa-
tion status.
Short-chain fatty acids
Within the GPCR gene superfamily GRP40–43 is a phylo-
genetically related group which comprises tandemly
encoded genes and shares approximately 30 % minimum
identity [62]. According to the SCFA type, acetate and
propionate produce a reduction in lipolytic activity
through GPR43 activation in mice studies [63]. However,
an increase of lipids in adipocytes via peroxisome
proliferator-activated receptor gamma 2 upregulation has
also been observed [64]. Acetate is an agonist for GPR43
and GPR41 receptors; in humans, GRP43 has a higher af-
finity to acetate than does GPR41, but in mice, GPR43
and GPR41 are activated equally by acetate [65]. Butyrate
has multiple effects, which involve several distinct mecha-
nisms of action such as epigenetic gene regulation [66],
acting as a signal molecule, targeting GPR43, GPR41 [62]
and GPR109A [67]. A study using sodium butyrate dem-
onstrated a reduction in proinflammatory cytokine and
chemokine levels in a steatosis rat model, via toll-like re-
ceptor and nuclear factor kappa-B inhibition, as well
PPAR-α recovery with the probable involvement of per-
oxisome proliferator-activated receptor gamma and coac-
tivator 1 alpha (PGC-1α) [7]. Moreover, butyrate improves
lipid profiles by enhancing tight junction protein expres-
sion, and by decreasing the levels of ALT, TNF-α and
serum endotoxin, apparently through 5′adenosine
monophosphate-activated protein kinase-related, nuclear
factor erythroid-derived 2, sterol regulatory element bind-
ing protein, PPARγ and NHE8 (sodium/hydrogen exchan-
ger 8) expression [15], and the enhanced Sp3 (Sodium
butyrate-mediated acetylation) interaction [68].
Evidence suggests that cell-surface receptors contrib-
ute to extracellular actions of SCFAs; however, intracel-
lular actions also play an essential role in the biological
effects and involve their function as potent epigenetic
modifiers related to the ability of butyrate and propion-
ate to inhibit histone deacetylases (HDACs), but not
acetate. To successfully achieve this intracellular func-
tion, SCFAs enter the cell through the Na+-coupled
high-affinity Slc5a8 (solute carrier gene family 5a, mem-
ber 8) transporter in order to have access to HDACs [67,
69]. Furthermore, butyrate promotes immune cell con-
version that consequently blockade dendritic cell devel-
opment; however, this mechanism has been related with
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dietary fiber content conditions, where transporter
would become essential only when dietary fiber intake is
sub-optimal [69].
According to lipid modifications, S-acylation is a
unique dynamic process that is reversible and promotes
the regulation of the subcellular distribution of key sig-
nalling molecules, which explains the importance of pro-
tein localization at several sites in the cell and hence
their function [70]. At mitochondrial level, dietary
SCFAs act through the repression of PPARγ expression,
subsequently AMP/ATP ratio increase leading to the ac-
tivation of AMPK and culminating in improving oxida-
tive metabolism in the liver and adipose tissue [71].
Medium-chain fatty acids and long-chain fatty acids
MCTs, precursors of MCFAs, are thought to enter hepa-
tocytes and mitochondria by a minimal use of the nor-
mal fatty acid transport systems or by diffusion, and
then degraded by direct thermogenesis [72]. MCFAs are
not incorporated into chylomicrons, instead they are
absorbed directly into the hepatic portal vein, suggesting
that they do not require transporters such as CD36 or
fatty acid transporter proteins to enter the liver [29, 72].
However, it has been demonstrated that GPR40 and
GPR120 receptors are involved with MCFA and LCFA
uptake respectively. These receptors are expressed in
enteroendocrine L and K cells producing glucagon-like
peptides (GLP-1 and 2) and gastric inhibitory peptides
[73–75]. MCFAs have several recognition and activation
mechanisms that need to be elucidated.
LCFAs (n-3) are involved in liver steatosis and inflam-
mation through decreased PPAR-α signaling and NF-kB
activation [41]. However, feeding mice with a HFD ag-
gravate liver injury increasing the expression levels of
proinflammatory and oxidative stress molecules, as well
as PUFA-oxidizing enzymes in a murine lipopolysacchar-
ide model [76]. Regarding other GPCR members,
GPR119 has been involved in decreasing cellular choles-
terol contents and inflammation inhibition, apparently
through the GLP-1 receptor signaling pathway in an in
vitro mice cell model [77]. GPR120 is highly expressed
in the digestive system, adipose tissues, lung, macro-
phages and also is present in the endocrine pancreas; it
seem to be specific for long-chain unsaturated fatty
acids, including n-3 PUFAs [78] where it appears to be
dispensable for the improved metabolic profile associ-
ated with diets enriched with these PUFAs [79].
In autoimmunity diseases, MCFAs or LCFAs, such as
lauric acid or palmitic acid, promote differentiation of
naive T cells into T helper 1 (Th1) and Th17 cells, pro-
moting inflammation apparently through activation of
the p38 MAPK pathway. On the other hand, SCFAs,
Fig. 2 Bioactive fatty acids function in the development of nonalcoholic fatty liver disease. Key: describing the different types of bioactive fatty
acids in relation to their sources, cell recognition mechanisms and biological effects
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propionate most potently, enhanced polarization of T
cells toward Treg cells probably through lipin2-JIP2
pathway, promoting suppression of inflammation. Trig-
gering factors have not been identified yet; however, cell-
surface receptors are the most likely targets [80, 81].
Moreover, several studies have been described as key
molecules that seem to be related to fatty acid regulation
mechanisms. A microsomal enzyme named after Evolv-
6 has been involved in saturated and monounsaturated
fatty acids regulation and in modifying fatty acid com-
position. In a LDL receptor-deficient murine model, ab-
sence of Evolv-6 showed a double effect in metabolism
of fatty acids with a decrease in lipid accumulation, chol-
esterol levels, hepatic inflammation and oxidative stress,
which leads a direct effect in NAFLD progression [82].
Sterol regulatory element-binding proteins (SREBPs) are
transcription factors that activate the synthesis of FAs,
triglycerides (TGs), and cholesterol; SREBPs overactiva-
tion in liver cause TG accumulation and hepatic steato-
sis. Thus, in a murine model it has been showed that the
elimination of nuclear SREBPs, prevents hypertriglyc-
eridemia induced by carbohydrate accumulation [83].
On the other hand, a membrane bound protein (SREBP-
2), activates enzyme-cholesterol biosynthesis genes, exert-
ing an important role on cholesterol homeostasis [84].
Although the published evidence shows discrepan-
cies, we should mention that the beneficial health ef-
fects of PUFAs could be dependent on their cis-
isomer configuration, which is the predominant bio-
active form. [85] Fatty acids in their configuration
have a rigid nonlinear structure, which enhances
membrane fluidity when incorporated into cells, pro-
mote cell-to-cell communication and help to maintain
normal homeostasis or prevent the development of
metabolic disorders [18]. The benefits of PUFAs could
be associated with their functions in mediating tran-
scription factors involving the expression of genes
inplicated in lipid synthesis and oxidation [42, 86].
Thus, biochemical configuration and gene expressions
should be considered to explain the observed discrep-
ancies in the actions of PUFAs.
Discussion
Fatty acid composition and carbon chain length are
both important in terms of their impact on human
health. The fat type in the diet affects the rate of
Fig. 3 Interaction between bioactive fatty acids and NAFLD development. Key: MCR, mitochondrial respiratory chain; SCFAs, short-chain fatty acid;
MCFAs, medium-chain fatty acid; PUFAs, polyunsaturated fatty acid
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hepatic triacylglycerol synthesis, which is an import-
ant determinant of plasma triacylglycerol concentra-
tions [28]. Moreover, the bioavailability of fatty acids
is another parameter to consider [42]. Alcohol inges-
tion along with PUFAs aggravates the production of
free radicals and aggravate oxidative stress [87]. Con-
sumption of foods with bioactive components within
an energy-restricted diet could be an option for the
treatment of patients with NAFLD. However, the
quality and combination of macronutrients are more
important than their isolated amounts.
Conclusion
The idea that several groups of lipids might provide health
benefits through changes in the tissue fatty acid composi-
tions or the induction of cell signaling pathways is intri-
guing (Fig. 2). It seems that bioactive fatty acids are
involved in modulating the activity of all cell types of the
liver during the development of obesity, NAFLD and liver
fibrosis (Fig. 3). However, more and better evidence is re-
quired regarding the roles of bioactive fatty acids in
humans, given the complicated clinical nature of NAFLD.
Improved methodological designs and larger sample sizes
are necessary to make decisions about whether to include
bioactive fatty acids in nutritional and clinical treatment
strategies for patients with NAFLD
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